Centro de Investigaciones Biologicas Margarita Salas (CIB-CSIC), Ramiro de Maeztu 9, 28040 Madrid, Spain.
Instituto de Filosofía, (IFS-CSIC), Albasanz 26, 28037 Madrid, Spain.
Curr Med Chem. 2021;28(20):3964-3979. doi: 10.2174/0929867327666201027153123.
In December 2019, a novel respiratory coronavirus named SARS-CoV-2 appeared in China, causing the disease termed COVID-19 that has caused millions of infections worldwide. In this article, we have analyzed existing evidence on the immune response against SARS coronaviruses in order to understand the possible outcome of a vaccine for COVID-19. From our analysis, it becomes clear that there is a big difference in the immune response against SARS in children, young adults and the elderly, both at the innate and adaptive levels. Taking this information into account, we have studied the strategies that are being used for the development of COVID-19 vaccines. We discussed the perspectives for obtention and worldwide distribution of reliable vaccines using this perspective. The conclusion is that different vaccines may be protective for different age segments within the population, depending on the strategy used for their design. Therefore, it will become necessary for several vaccines to reach the finish line, not only to ensure availability, but also to guarantee an adequate immune response at the individual level.
2019 年 12 月,一种新型呼吸道冠状病毒 SARS-CoV-2 在中国出现,引发了被称为 COVID-19 的疾病,该疾病已在全球范围内导致数百万人感染。在本文中,我们分析了针对 SARS 冠状病毒的现有免疫反应证据,以了解针对 COVID-19 的疫苗可能产生的结果。从我们的分析中可以清楚地看出,儿童、年轻人和老年人对 SARS 的免疫反应在先天和适应性水平上都存在很大差异。考虑到这一信息,我们研究了用于开发 COVID-19 疫苗的策略。我们从这个角度讨论了获得和在全球范围内分发可靠疫苗的前景。结论是,根据设计策略的不同,不同的疫苗可能对人群中的不同年龄组具有保护作用。因此,不仅需要确保供应,还需要确保个体水平的适当免疫反应,因此需要几种疫苗才能达到终点。